Stock Price Movement and Market Context
On the trading day, Lincoln Pharmaceuticals Ltd’s stock touched an intraday low of Rs.454.55, closing with a day change of -1.39%. This decline extended a three-day losing streak, during which the stock has fallen by 5.1%. The share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
In comparison, the broader Sensex index opened flat but moved into negative territory, trading at 83,017.27 points, down 0.27% or 38.80 points. The Sensex remains approximately 3.78% below its 52-week high of 86,159.02, and has experienced a three-week consecutive decline, losing 3.2% over that period. While the Sensex trades below its 50-day moving average, the 50DMA remains above the 200DMA, indicating mixed technical signals for the broader market.
Long-Term and Recent Performance Analysis
Lincoln Pharmaceuticals Ltd has underperformed significantly over the past year, with a total return of -42.36%, contrasting sharply with the Sensex’s positive 7.71% return over the same period. The stock’s 52-week high was Rs.819.95, highlighting the extent of the recent decline.
Over the last five years, the company’s net sales have grown at a modest annual rate of 9.21%, while operating profit has increased at a slower pace of 5.37%. These growth rates are below expectations for the Pharmaceuticals & Biotechnology sector, contributing to the stock’s subdued performance.
Fresh entry alert! This Small Cap from Electronics & Appliances sector is already turning heads in our Top 1% club. Get ahead of the market now!
- - New Top 1% entry
- - Market attention building
- - Early positioning opportunity
Quarterly Financial Results and Profitability Metrics
The company’s recent quarterly results for September 2025 revealed a decline in profitability. Profit After Tax (PAT) stood at Rs.19.98 crores, down by 24.1% compared to the previous quarter. Profit Before Tax excluding other income (PBT less OI) was Rs.21.58 crores, reflecting a decrease of 12.98%. These figures indicate a contraction in earnings despite stable revenue streams.
Return on Capital Employed (ROCE) for the half-year period was reported at 15.46%, marking the lowest level in recent assessments. Return on Equity (ROE) remains at 11.2%, which, while moderate, has not been sufficient to drive investor confidence amid declining profit margins.
Valuation and Shareholding Patterns
Lincoln Pharmaceuticals Ltd’s stock currently trades at a Price to Book Value ratio of 1.3, suggesting a valuation that is broadly in line with its peers’ historical averages. The company maintains a low average Debt to Equity ratio of zero, indicating a conservative capital structure with minimal leverage.
Despite the company’s size, domestic mutual funds hold no stake in Lincoln Pharmaceuticals Ltd. Given that domestic mutual funds typically conduct thorough on-the-ground research, their absence from the shareholding pattern may reflect reservations about the company’s current valuation or business outlook.
Comparative Performance and Sector Positioning
Over the past three years, Lincoln Pharmaceuticals Ltd has consistently underperformed the BSE500 index, as well as its sector peers. The stock’s negative returns over one year and three months further underscore its challenges in maintaining competitive growth and profitability within the Pharmaceuticals & Biotechnology sector.
Profitability has also declined over the past year, with profits falling by 17.2%, compounding the stock’s downward trajectory. This trend contrasts with the broader sector’s performance, which has shown more resilience despite recent market volatility.
Holding Lincoln Pharmaceuticals Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Mojo Score and Rating Update
MarketsMOJO assigns Lincoln Pharmaceuticals Ltd a Mojo Score of 37.0, categorising it with a Sell grade as of 5 August 2025. This represents an upgrade from a previous Strong Sell rating, reflecting some improvement in certain metrics but still indicating caution. The company’s Market Cap Grade stands at 4, which is moderate but not indicative of strong market capitalisation strength.
The downgrade in the Mojo Grade from Strong Sell to Sell suggests that while some aspects of the company’s fundamentals may have stabilised, overall performance and outlook remain subdued.
Summary of Key Metrics
To summarise, Lincoln Pharmaceuticals Ltd’s stock has reached a new 52-week low of Rs.454.55 amid a backdrop of declining profitability, subdued sales growth, and underwhelming returns relative to the broader market and sector peers. The stock’s technical indicators remain weak, with prices below all major moving averages and a recent three-day losing streak.
Financial results highlight a contraction in earnings and returns, while valuation metrics suggest the stock is fairly priced but not compelling. The absence of domestic mutual fund holdings further emphasises the cautious stance within institutional circles.
Overall, the stock’s recent performance and fundamental data illustrate the challenges faced by Lincoln Pharmaceuticals Ltd in maintaining growth and profitability in a competitive sector environment.
Unlock special upgrade rates for a limited period. Start Saving Now →
